| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
43,320,000 |
| Market
Cap: |
38.12(M) |
| Last
Volume: |
407,634 |
Avg
Vol: |
406,502 |
| 52
Week Range: |
$0.7977 - $4.03 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytosorbents is engaged in the treatment of life-threatening conditions in the intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology. Co. has several products commercialized and in development based on this technology platform. CytoSorb, Co.'s primary product, is approved in the European Union as an extracorporeal cytokine absorber, designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
229,325 |
245,625 |
376,222 |
| Total Buy Value |
$0 |
$305,002 |
$355,029 |
$587,331 |
| Total People Bought |
0 |
8 |
8 |
9 |
| Total Buy Transactions |
0 |
8 |
12 |
27 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Deliargyris Efthymios |
Chief Medical Officer |
• – – |
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
61,000 |
409,433 |
|
- |
|
| Chan Phillip P. |
Chief Executive Officer |
• • – |
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
96,000 |
1,164,704 |
|
- |
|
| Capponi Vincent |
President and COO |
• – – |
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
81,000 |
665,134 |
|
- |
|
| Bloch Kathleen P. |
Chief Financial Officer |
• – – |
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
532,941 |
|
- |
|
| Kim Jiny |
Director |
– • – |
2023-12-13 |
4 |
B |
$1.33 |
$10,000 |
D/D |
7,519 |
77,819 |
2.39 |
-54% |
|
| Bator Michael G. |
Director |
– • – |
2023-12-13 |
4 |
B |
$1.33 |
$50,000 |
D/D |
37,594 |
125,394 |
2.39 |
-54% |
|
| Deliargyris Efthymios |
Chief Medical Officer |
• – – |
2023-12-13 |
4 |
B |
$1.33 |
$30,001 |
D/D |
22,557 |
348,433 |
2.74 |
-54% |
|
| Capponi Vincent |
President & COO |
• – – |
2023-12-13 |
4 |
B |
$1.33 |
$25,000 |
D/D |
18,797 |
584,134 |
2.74 |
-54% |
|
| Chan Phillip P. |
Chief Executive Officer |
• • – |
2023-12-13 |
4 |
B |
$1.33 |
$100,000 |
D/D |
75,188 |
1,068,704 |
2.81 |
-54% |
|
| Sobel Alan D. |
Director |
– • – |
2023-12-13 |
4 |
B |
$1.33 |
$30,001 |
D/D |
22,557 |
101,857 |
2.39 |
-54% |
|
| Bloch Kathleen P. |
Chief Financial Officer |
• – – |
2023-12-13 |
4 |
B |
$1.33 |
$50,000 |
D/D |
37,594 |
467,941 |
2.74 |
-54% |
|
| Jones Edward Raymond |
Director |
– • – |
2023-12-13 |
4 |
B |
$1.33 |
$10,000 |
D/D |
7,519 |
88,834 |
2.39 |
-54% |
|
| Bloch Kathleen P. |
Chief Financial Officer |
• – – |
2023-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
442,347 |
|
- |
|
| Damico Alex |
Chief Financial OfficerOfficer |
• – – |
2023-08-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
210,000 |
|
-44% |
|
| Bator Michael G. |
Director |
– • – |
2023-08-07 |
4 |
B |
$3.15 |
$6,350 |
D/D |
2,000 |
87,800 |
2.39 |
-44% |
|
| Bator Michael G. |
Director |
– • – |
2023-08-04 |
4 |
B |
$3.23 |
$3,230 |
D/D |
1,000 |
85,800 |
2.31 |
-55% |
|
| Capponi Vincent |
President & COO |
• – – |
2023-07-07 |
4 |
A |
$0.00 |
$0 |
D/D |
73,000 |
576,153 |
|
- |
|
| Deliargyris Efthymios |
Chief Medical Officer |
• – – |
2023-07-07 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
331,648 |
|
- |
|
| Chan Phillip P. |
Chief Executive Officer |
• • – |
2023-07-07 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
1,006,548 |
|
- |
|
| Bloch Kathleen P. |
Interim CFO |
• – – |
2023-05-25 |
4 |
B |
$2.84 |
$9,389 |
I/I |
3,300 |
47,000 |
1.99 |
-40% |
|
| Bloch Kathleen P. |
Interim CFO |
• – – |
2023-05-10 |
4 |
B |
$3.06 |
$31,058 |
I/I |
10,000 |
43,700 |
1.99 |
-39% |
|
| Capponi Vincent |
See Remarks |
• – – |
2023-04-04 |
4 |
OE |
$2.88 |
$28,750 |
D/D |
10,000 |
511,989 |
|
- |
|
| Chan Phillip P. |
Chief Executive Officer |
• – – |
2023-04-03 |
4 |
OE |
$2.88 |
$87,688 |
D/D |
30,500 |
927,779 |
|
- |
|
| Sobel Alan D. |
Director |
– • – |
2023-02-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,000 |
0 |
|
- |
|
| Sobel Alan D. |
Director |
– • – |
2023-02-27 |
4 |
GA |
$0.00 |
$0 |
D/D |
2,000 |
81,300 |
|
- |
|
361 Records found
|
|
Page 1 of 15 |
|
|
0.06 (7.4%) 
